Stifel Nicolaus Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $10.00

Alto Neuroscience (NYSE:ANRO) had its target price decreased by equities researchers at Stifel Nicolaus from $32.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 116.92% from the stock’s current price.

Several other brokerages have also recently issued reports on ANRO. Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird reduced their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Trading Up 1.8 %

ANRO opened at $4.61 on Wednesday. The business has a fifty day moving average of $10.02 and a 200 day moving average of $11.46. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85. Alto Neuroscience has a 52-week low of $3.61 and a 52-week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. As a group, equities analysts predict that Alto Neuroscience will post -2.63 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several hedge funds and other institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. acquired a new position in Alto Neuroscience during the 1st quarter valued at about $21,267,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Alto Neuroscience in the 1st quarter valued at approximately $9,788,000. Vanguard Group Inc. acquired a new stake in Alto Neuroscience in the 1st quarter worth approximately $8,233,000. Jennison Associates LLC grew its position in Alto Neuroscience by 80.3% during the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after purchasing an additional 370,612 shares during the last quarter. Finally, Artal Group S.A. acquired a new position in Alto Neuroscience during the 1st quarter valued at approximately $5,372,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.